Do we always need to treat patients with spinal muscular atrophy? A personal view and experience.
Caterina AgostoEleonora SalamonAntuan DivisicFrancesca BenedettiLuca GiacomelliAashni ShahGiorgio PerilongoFranca BeniniPublished in: Orphanet journal of rare diseases (2021)
Our analysis further supports the findings reported in the study by Audic et al. We believe that a wider use of nusinersen in clinical practice would require a comprehensive assessment of its actual benefits weighed against the discomfort caused to patients, as well as the identification of the patients who may obtain the best benefits from this treatment.